The American Society of Clinical Oncology and Friends of Cancer Research jointly issued recommendations to broaden eligibility criteria in cancer clinical trials, with the goal of making clinical trials more accessible to patients.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
